SCHEMBL6080911

SCHEMBL6080911

COC(=O)c1cc(O)c2cc(-c3cccnc3)cc(O)c2n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 1/20 0.50
CYP11B1 P15538 1/20 0.50
CYP11B2 P19099 1/20 0.50
L3MBTL1 Q9Y468 2/20 0.49
KDM4E B2RXH2 2/20 0.49
NPC1 O15118 2/20 0.49
RAB9A P51151 1/20 0.49
NR4A2 P43354 3/20 0.48
SLC2A1 P11166 1/20 0.45
NEK1 Q96PY6 1/20 0.43
ALDH1A1 P00352 1/20 0.43
MKNK1 Q9BUB5 2/20 0.42
MKNK2 Q9HBH9 2/20 0.42
ERN1 O75460 1/20 0.41
ABL1 P00519 1/20 0.41
BCR P11274 1/20 0.41
SRC P12931 1/20 0.41
CFTR P13569 1/20 0.40
MAPT P10636 1/20 0.40
ABCG2 Q9UNQ0 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6080980 0.85 L3MBTL1 (0.53) CYP19A1CYP11B1CYP11B2L3MBTL1KDM4E
SCHEMBL6080624 0.83 CYP11B1 (0.48) CYP19A1CYP11B1CYP11B2NR4A2MAPT
SCHEMBL6081550 0.82 HSD17B10 (0.39) KDM4ENPC1RAB9AALDH1A1ERN1
SCHEMBL6080590 0.79 ALDH1A1 (0.45) CYP11B1CYP11B2L3MBTL1KDM4ENPC1
SCHEMBL6079342 0.79 SMN1; SMN2 (0.42) L3MBTL1KDM4ENPC1RAB9AALDH1A1
SCHEMBL6080387 0.77 NOTUM (0.50) KDM4ELCK
SCHEMBL6080426 0.76 NQO2 (0.43) KDM4ENR4A2ALDH1A1MAPT
SCHEMBL6081303 0.76 DHODH (0.43) KDM4ENR4A2ALDH1A1
SCHEMBL3713518 0.74 CYP11B1 (0.55) CYP19A1CYP11B1CYP11B2KDM4ENPC1
SCHEMBL6080283 0.73 EGFR (0.42) CYP19A1CYP11B1CYP11B2L3MBTL1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NEURO3D (FR) 2006-08-17 US claimed
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NEURO3D (FR) 2006-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NQO1, NQO2, RECQL CYP19A1 988/4885CYP11B1 633/4885CYP11B2 477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.